penumbra - PEN
PEN
Close Chg Chg %
336.41 -1.35 -0.40%
Closed Market
335.06
-1.35 (0.40%)
Volume: 559.64K
Last Updated:
Mar 27, 2026, 3:59 PM EDT
Company Overview: penumbra - PEN
PEN Key Data
| Open $336.26 | Day Range 334.81 - 336.36 |
| 52 Week Range 221.26 - 362.41 | Market Cap $13.20B |
| Shares Outstanding 39.24M | Public Float 38.02M |
| Beta 0.81 | Rev. Per Employee N/A |
| P/E Ratio 74.39 | EPS $4.56 |
| Yield 0.00% | Dividend N/A |
| EX-DIVIDEND DATE | SHORT INTEREST N/A |
| AVERAGE VOLUME 602.36K |
PEN Performance
| 1 Week | 0.17% | ||
| 1 Month | -2.31% | ||
| 3 Months | 6.14% | ||
| 1 Year | 25.74% | ||
| 5 Years | 27.93% |
PEN Analyst Ratings
- Sell
- Under
- Hold
- Over
- Buy
Number of Ratings
18
Full Ratings ➔
About penumbra - PEN
Penumbra, Inc. is a thrombectomy company, which designs, develops, manufactures, and markets innovative medical products. It offers neurovascular thrombectomy and embolization and access technologies, neurosurgical tools, Penumbra LANTERN Delivery Microcatheter, and Penumbra Occlusion Device system. The company was founded by Arani Bose and Adam Elsesser on June 21, 2004 and is headquartered in Alameda, CA.
PEN At a Glance
Penumbra, Inc.
One Penumbra Place
Alameda, California 94502
| Phone | 1-510-748-3200 | Revenue | 1.40B | |
| Industry | Medical Specialties | Net Income | 177.69M | |
| Sector | Health Technology | 2025 Sales Growth | 17.499% | |
| Fiscal Year-end | 12 / 2026 | Employees | 4,700 | |
| View SEC Filings |
PEN Valuation
| P/E Current | 74.393 |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | 68.752 |
| Price to Sales Ratio | 8.703 |
| Price to Book Ratio | 8.544 |
| Price to Cash Flow Ratio | 51.19 |
| Enterprise Value to EBITDA | 56.543 |
| Enterprise Value to Sales | 8.471 |
| Total Debt to Enterprise Value | 0.018 |
PEN Efficiency
| Revenue/Employee | 298,652.128 |
| Income Per Employee | 37,805.745 |
| Receivables Turnover | 7.387 |
| Total Asset Turnover | 0.836 |
PEN Liquidity
| Current Ratio | 6.644 |
| Quick Ratio | 4.287 |
| Cash Ratio | 2.975 |
PEN Profitability
| Gross Margin | 65.66 |
| Operating Margin | 13.482 |
| Pretax Margin | 14.614 |
| Net Margin | 12.659 |
| Return on Assets | 10.578 |
| Return on Equity | 13.782 |
| Return on Total Capital | 10.787 |
| Return on Invested Capital | 11.882 |
PEN Capital Structure
| Total Debt to Total Equity | 15.389 |
| Total Debt to Total Capital | 13.337 |
| Total Debt to Total Assets | 12.028 |
| Long-Term Debt to Equity | 14.252 |
| Long-Term Debt to Total Capital | 12.351 |
- Income Statement
- Balance Sheet
- Cash Flow Statement
Annual Financials for Penumbra - PEN
Collapse All in section
| All values USD millions. | 2022 | 2023 | 2024 | 2025 | 5-year trend |
|---|---|---|---|---|---|
Sales/Revenue
| 847.13M | 1.06B | 1.19B | 1.40B | |
Sales Growth
| +13.32% | +24.95% | +12.86% | +17.50% | |
Cost of Goods Sold (COGS) incl D&A
| 320.84M | 385.83M | 444.81M | 482.02M | |
COGS excluding D&A
| - | - | - | - | - |
Depreciation & Amortization Expense
| 27.57M | 30.61M | 27.24M | 21.05M | |
Depreciation
| 18.39M | 20.39M | 21.79M | 20.34M | |
Amortization of Intangibles
| 9.18M | 10.21M | 5.45M | 712.00K | |
COGS Growth
| +16.74% | +20.25% | +15.29% | +8.37% | |
Gross Income
| 526.29M | 672.69M | 749.81M | 921.65M | |
Gross Income Growth
| +11.32% | +27.82% | +11.46% | +22.92% | |
Gross Profit Margin
| +62.13% | +63.55% | +62.77% | +65.66% |
| 2022 | 2023 | 2024 | 2025 | 5-year trend | |
|---|---|---|---|---|---|
SG&A Expense
| 520.21M | 580.93M | 663.58M | 732.40M | |
Research & Development
| 79.41M | 84.42M | 94.78M | 69.43M | |
Other SG&A
| 440.80M | 496.50M | 568.80M | 662.97M | |
SGA Growth
| +8.32% | +11.67% | +14.23% | +10.37% | |
Other Operating Expense
| - | - | - | - | - |
Unusual Expense
| - | - | 18.21M | 76.94M | - |
EBIT after Unusual Expense
| 6.08M | 73.55M | 9.28M | 189.25M | |
Non Operating Income/Expense
| (2.19M) | 7.84M | 13.01M | 17.19M | |
Non-Operating Interest Income
| 137.00K | 6.83M | 13.69M | 16.29M | |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Interest Expense
| - | 1.74M | 1.42M | 1.31M | |
Interest Expense Growth
| - | - | -18.46% | -7.55% | - |
Gross Interest Expense
| - | 1.74M | 1.42M | 1.31M | |
Interest Capitalized
| - | - | - | - | - |
Pretax Income
| 3.89M | 79.65M | 20.87M | 205.13M | |
Pretax Income Growth
| +137.06% | +1,946.51% | -73.80% | +882.92% | |
Pretax Margin
| +0.46% | +7.52% | +1.75% | +14.61% | |
Income Tax
| 5.89M | (11.30M) | 6.86M | 27.44M | |
Income Tax - Current - Domestic
| 3.10M | 8.93M | 20.57M | 3.30M | |
Income Tax - Current - Foreign
| 1.73M | 4.89M | 2.62M | 3.14M | |
Income Tax - Deferred - Domestic
| 1.54M | (23.87M) | (15.93M) | 20.78M | |
Income Tax - Deferred - Foreign
| (476.00K) | (1.25M) | (404.00K) | 221.00K | |
Income Tax Credits
| - | - | - | - | - |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Other After Tax Income (Expense)
| - | - | - | - | - |
Consolidated Net Income
| (2.00M) | 90.95M | 14.01M | 177.69M | |
Minority Interest Expense
| - | - | - | - | - |
Net Income
| (2.00M) | 90.95M | 14.01M | 177.69M | |
Net Income Growth
| -137.89% | +4,643.16% | -84.59% | +1,168.11% | |
Net Margin Growth
| -0.24% | +8.59% | +1.17% | +12.66% | |
Extraordinaries & Discontinued Operations
| - | - | - | - | - |
Discontinued Operations
| - | - | - | - | - |
Net Income After Extraordinaries
| (2.00M) | 90.95M | 14.01M | 177.69M | |
Preferred Dividends
| - | - | - | - | - |
Net Income Available to Common
| (2.00M) | 90.95M | 14.01M | 177.69M | |
EPS (Basic)
| -0.0529 | 2.3685 | 0.3627 | 4.5656 | |
EPS (Basic) Growth
| -136.81% | +4,577.32% | -84.69% | +1,158.78% | |
Basic Shares Outstanding
| 37.84M | 38.40M | 38.63M | 38.92M | |
EPS (Diluted)
| -0.0529 | 2.3193 | 0.3568 | 4.5222 | |
EPS (Diluted) Growth
| -137.92% | +4,484.31% | -84.62% | +1,167.43% | |
Diluted Shares Outstanding
| 37.84M | 39.22M | 39.27M | 39.29M | |
EBITDA
| 33.66M | 122.37M | 113.47M | 210.30M | |
EBITDA Growth
| +180.72% | +263.60% | -7.28% | +85.34% | |
EBITDA Margin
| +3.97% | +11.56% | +9.50% | +14.98% |
Snapshot
| Average Recommendation | HOLD | Average Target Price | 369.286 | |
| Number of Ratings | 18 | Current Quarters Estimate | 1.064 | |
| FY Report Date | 03 / 2026 | Current Year's Estimate | 5.008 | |
| Last Quarter’s Earnings | 1.18 | Median PE on CY Estimate | N/A | |
| Year Ago Earnings | 3.84 | Next Fiscal Year Estimate | 6.329 | |
| Median PE on Next FY Estimate | N/A |
Earnings Per Share
| This Quarter | Next Quarter | This Fiscal | Next Fiscal | |
|---|---|---|---|---|
| # of Estimates | 13 | 13 | 15 | 13 |
| Mean Estimate | 1.06 | 1.19 | 5.01 | 6.33 |
| High Estimates | 1.14 | 1.23 | 5.19 | 6.84 |
| Low Estimate | 0.93 | 1.11 | 4.64 | 5.63 |
| Coefficient of Variance | 5.64 | 3.33 | 3.30 | 5.16 |
Analysts Recommendations
| Current | 1 Month Ago | 3 Months Ago | |
|---|---|---|---|
| BUY | 3 | 4 | 17 |
| OVERWEIGHT | 0 | 0 | 1 |
| HOLD | 14 | 15 | 2 |
| UNDERWEIGHT | 1 | 0 | 0 |
| SELL | 0 | 0 | 1 |
| MEAN | Hold | Hold | Buy |
SEC Filings for Penumbra - PEN
| Filing Date | Type | Category | Amended |
|---|---|---|---|
| No results | |||
Insider Actions for Penumbra - PEN
| Date | Name | Shares | Transaction | Value |
|---|---|---|---|---|
| Jan 8, 2026 | Thomas C. Wilder Director | N/A | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $310.72 per share | 0.00 |
| Nov 20, 2025 | Lambert Shiu Chief Accounting Officer | 32,491 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $280.07 per share | 9,099,754.37 |
| Nov 20, 2025 | Maggie S. Yuen Chief Financial Officer | 13,303 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $280.07 per share | 3,725,771.21 |
| Nov 20, 2025 | Maggie S. Yuen Chief Financial Officer | 12,976 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $280.07 per share | 3,634,188.32 |
| Nov 20, 2025 | Johanna Roberts EVP, Gen. Counsel & Secretary | 63,501 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $280.07 per share | 17,784,725.07 |
| Nov 20, 2025 | Johanna Roberts EVP, Gen. Counsel & Secretary | 62,956 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $280.07 per share | 17,632,086.92 |
| Nov 20, 2025 | Maggie S. Yuen Chief Financial Officer | 16,556 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Nov 20, 2025 | Lambert Shiu Chief Accounting Officer | 31,985 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $280.07 per share | 8,958,038.95 |
| Nov 20, 2025 | Lambert Shiu Chief Accounting Officer | 35,565 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Nov 20, 2025 | Shruthi Narayan President | 26,603 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $280.07 per share | 7,450,702.21 |
| Nov 20, 2025 | Johanna Roberts EVP, Gen. Counsel & Secretary | 66,536 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Apr 18, 2025 | Bridget O'Rourke Director | 5,523 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $271.21 per share | 1,497,892.83 |
| Apr 7, 2025 | Adam Elsesser CEO and President; Director | 62,452 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $272 per share | 16,986,944.00 |
| Apr 7, 2025 | Adam Elsesser CEO and President; Director | 58,244 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $273.71 per share | 15,941,965.24 |
| Apr 7, 2025 | Adam Elsesser CEO and President; Director | 64,102 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $270.34 per share | 17,329,334.68 |
| Apr 7, 2025 | Adam Elsesser CEO and President; Director | 52,960 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $275.24 per share | 14,576,710.40 |
| Apr 7, 2025 | Adam Elsesser CEO and President; Director | 52,560 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $275.99 per share | 14,506,034.40 |
| Apr 7, 2025 | Adam Elsesser CEO and President; Director | 52,495 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $277.63 per share | 14,574,186.85 |
| Apr 7, 2025 | Adam Elsesser CEO and President; Director | 307,740 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Apr 7, 2025 | Adam Elsesser CEO and President; Director | 65,002 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $269.25 per share | 17,501,788.50 |